PriMera Scientific Medicine and Public Health (ISSN: 2833-5627)

Review Article

Volume 3 Issue 6

A Review on Health Care Surveillance of PCOD

Anshika Pandey, Arun Kumar Pal*, Gagan Chawla, Shazda Ansari and Jaydev Mandal

November 08, 2023

DOI : 10.56831/PSMPH-03-102

View PDF

Abstract

The "Healthcare Surveillance of PCOD" study aims to understand the prevalence, symptoms, management strategies, and perceptions of PCOD among patients. Findings indicate that PCOD predominantly affects unmarried women in the age group of 18-25 years, with the most common symptoms being irregular periods, weight gain, acne, hirsutism, hair loss, and infertility. The majority of patients sought medical intervention, with a significant proportion opting for medication and diet and exercise. The perception regarding management of PCOD through lifestyle changes varied, with some believing it to be effective, while others expressed scepticism. Lifestyle changes were adopted by a majority of patients, with varying levels of success reported.

Keyword: PCOD; irregular periods; hair loss

References

  1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. “Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)”. Human Reproduction 19.1 (2004): 41-47.
  2. Diamanti-Kandarakis E and Dunaif A. “Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications”. Endocrine Reviews 33.6 (2012): 981-1030.
  3. Teede H., et al. “Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline”. Medical Journal of Australia 195.6 (2010): S65-S112.
  4. Legro RS., et al. “Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline”. The Journal of Clinical Endocrinology & Metabolism 98.12 (2013): 4565-4592.
  5. Moran LJ., et al. “Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis”. Human Reproduction Update 16.4 (2010): 347-363.
  6. Azziz R., et al. “Polycystic ovary syndrome”. Nature Reviews Disease Primers 2 (2016): 16057.
  7. Dumesic DA., et al. “Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome”. Endocrine Reviews 36.5 (2016): 487-525.
  8. Escobar-Morreale HF. “Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment”. Nature Reviews Endocrinology 14.5 (2018): 270-284.
  9. Asemi Z., et al. “Effects of magnesium and vitamin E co-supplementation on hormonal status and biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome”. Journal of Ovarian Research 12.1 (2019): 1-9.
  10. Cesta CE., et al. “Polycystic ovary syndrome and cardiovascular disease in a retrospective cohort: a matched analysis”. American Journal of Obstetrics & Gynecology MFM 2.3 (2020): 100176.
  11. Escobar-Morreale HF., et al. “The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery”. J Clin Endocrinol Metab 90.12 (2005): 6364-6369.
  12. Pasquali R and Gambineri A. “Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age”. Ann N Y Acad Sci 1092 (2006): 158-174.
  13. Iatrakis G., et al. “Use of oral contraceptives for the prevention of endometrial cancer in women with polycystic ovary syndrome”. Gynecol Endocrinol 31.5 (2015): 390-393.
  14. American Society for Reproductive Medicine. “Diagnostic evaluation of the infertile female: a committee opinion”. Fertil Sterile 103.6 (2015): e44-50.
  15. American College of Obstetricians and Gynecologists. “ACOG Practice bulletin no. 194: polycystic ovary syndrome”. Obstet Gynecol 131.6 (2018): e157-e171.